ES2053953T3 - Uso de fracciones de heparina o fragmentos de heparina. - Google Patents

Uso de fracciones de heparina o fragmentos de heparina.

Info

Publication number
ES2053953T3
ES2053953T3 ES89202061T ES89202061T ES2053953T3 ES 2053953 T3 ES2053953 T3 ES 2053953T3 ES 89202061 T ES89202061 T ES 89202061T ES 89202061 T ES89202061 T ES 89202061T ES 2053953 T3 ES2053953 T3 ES 2053953T3
Authority
ES
Spain
Prior art keywords
heparin
fractions
fragments
heparin fragments
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89202061T
Other languages
English (en)
Inventor
Henricus Carl J Ottenheijm
Franciscus C Den Hollander
Erik Desire A De Clercq
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo NV
Original Assignee
Akzo NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo NV filed Critical Akzo NV
Application granted granted Critical
Publication of ES2053953T3 publication Critical patent/ES2053953T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA INVENCION SE REFIERE AL USO DE FRAGMENTOS Y FRACCIONES DE HEPARINA CON ACTIVIDAD ANTITROMBINA, QUE ES MENOS QUE 50 U/MG, PARA LA PREPARACION DE UN MEDICAMENTO QUE INHIBE O IMPIDE LA REPRODUCCION DEL VIRUS HIV DE INMUNODEFICIENCIA HUMANO.
ES89202061T 1988-08-24 1989-08-09 Uso de fracciones de heparina o fragmentos de heparina. Expired - Lifetime ES2053953T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL8802087 1988-08-24

Publications (1)

Publication Number Publication Date
ES2053953T3 true ES2053953T3 (es) 1994-08-01

Family

ID=19852794

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89202061T Expired - Lifetime ES2053953T3 (es) 1988-08-24 1989-08-09 Uso de fracciones de heparina o fragmentos de heparina.

Country Status (13)

Country Link
EP (1) EP0355905B1 (es)
JP (1) JPH02108624A (es)
KR (1) KR0143084B1 (es)
AT (1) ATE84217T1 (es)
AU (1) AU617850B2 (es)
CA (1) CA1330305C (es)
DE (1) DE68904264T2 (es)
DK (1) DK416089A (es)
ES (1) ES2053953T3 (es)
IE (1) IE61565B1 (es)
NZ (1) NZ230394A (es)
PT (1) PT91524B (es)
ZA (1) ZA896231B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08109134A (ja) * 1994-10-11 1996-04-30 Sanwa Kagaku Kenkyusho Co Ltd 細胞変成抑制並びに臓器毒性軽減剤
US5744457A (en) * 1995-03-31 1998-04-28 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US6001820A (en) * 1995-03-31 1999-12-14 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5763427A (en) * 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
DE69623840D1 (de) * 1995-03-31 2002-10-31 Hamilton Civic Hospitals Res Zusammensetzung zur Hemmung der Thromboseentstehung
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
DE19836339B4 (de) 1998-08-11 2011-12-22 N.V. Nutricia Kohlenhydratmischung
EP1331932B1 (en) * 2000-11-09 2007-04-04 Contrimmune Biotechnology Inc. Use of xestospongin c for treating or preventing hiv infection
FR2838649B1 (fr) * 2002-04-19 2006-01-13 Commissariat Energie Atomique Composition anti-vih, procede de fabrication et medicament
US20040229778A1 (en) * 2003-05-13 2004-11-18 Elmaleh David R. Pharmaceutical compositions of antithrombin III for the treatment of retroviral diseases
EP1597978A1 (en) 2004-05-17 2005-11-23 Nutricia N.V. Synergism of GOS and polyfructose
US8252769B2 (en) 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
EP1721611A1 (en) * 2005-04-21 2006-11-15 N.V. Nutricia Nutritional supplement with oligosaccharides for a category of HIV patients
DE112010002825B4 (de) 2009-07-03 2017-09-14 Honda Motor Co., Ltd. Fahrzeugsitz
JP5757639B2 (ja) 2010-09-14 2015-07-29 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ セルピンフィンガー融合ポリペプチド

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3422518A1 (de) * 1984-06-16 1985-12-19 B. Braun Melsungen Ag, 3508 Melsungen Heparin-derivate, verfahren zu ihrer herstellung, diese enthaltende arzneimittel und ihre verwendung bei der behandlung von fettstoffwechselstoerungen
ZA878877B (en) * 1986-11-29 1988-05-24 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Treatment of diseases caused by viruses
WO1990003791A1 (en) * 1988-10-05 1990-04-19 Nicola Diferrante Methods for interfering with hiv multiplication and composition for the treatment of aids

Also Published As

Publication number Publication date
PT91524B (pt) 1995-07-18
ZA896231B (en) 1990-05-30
JPH02108624A (ja) 1990-04-20
DE68904264D1 (de) 1993-02-18
ATE84217T1 (de) 1993-01-15
EP0355905B1 (en) 1993-01-07
KR900002788A (ko) 1990-03-23
DK416089D0 (da) 1989-08-23
PT91524A (pt) 1990-03-08
IE61565B1 (en) 1994-11-16
IE892565L (en) 1990-02-24
AU4001289A (en) 1990-03-01
DK416089A (da) 1990-02-25
KR0143084B1 (ko) 1998-07-15
EP0355905A1 (en) 1990-02-28
AU617850B2 (en) 1991-12-05
DE68904264T2 (de) 1993-05-27
NZ230394A (en) 1997-02-24
CA1330305C (en) 1994-06-21

Similar Documents

Publication Publication Date Title
ZA896231B (en) Heparin fragments and fractions with anti-hiv action
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
FI952302L (fi) Pyran-2-onit ja 5,6-dihydropyranonit, jotka ovat käyttökelpoisia HIV:n ja muiden retrovirusten hoidossa
ES2130114T3 (es) 5,11-dihidro-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepinas y su uso en la prevencion o tratamiento de infeccion por hiv.
AU3063389A (en) Hiv-2-type retroviruses of primates, vaccines, diagnostic and pharmaceutical compositions
NL960024I2 (nl) Farmaceutisch preparaat omvattend 3'-deoxythymidine-2'-een (3'-deoxy-2',3'-didehydrothymidine) voor de behandeling van met retrovirus besmette patiënten.
ZA885577B (en) A pharmaceutical combination product and the preparation and use thereof
ATE130516T1 (de) Anti-hiv-heilmittel.
EP0311107A3 (en) Anti-hiv active 3'-fluoro-purine-2',3'-dideoxyribosides
DE68914990D1 (de) Verfahren zur inhibierung der wirkung des menschlichen immunschwäche-virus (hiv) in vivo.
AU2833789A (en) Non-reverting rna viruses
ES2108680T3 (es) Uso del derivado n-n-butilo de desoxinojirimicina en la fabricacion de un medicamento.
IL81568A0 (en) Plasmids which inhibit human t-cell lymphotropic virus type iii replication
WO1990005523A3 (en) Phenanthrolinedicarboxylate esters, 4-aminoquinoline and isoquinoline derivatives as inhibitors of hiv reverse transcriptase
KR950702838A (ko) 인터루킨-4(IL-4)를 사용한 사람 면역결핍 바이러스(HIV) 복제의 억제방법(Method for inhibiting HIV replication using IL-4)
GR1000618B (el) Μεθοδος αναστολης hiv χρησιμοποιωντας συνεργιστικους συνδυασμους νουκλεοσιδικων παραγωγων.
FI883735A7 (fi) Ihmisen immuunikatoviruksen, tyyppi 1, antigeenien valmistus ja käyttö diagnostisena ja terapeuttisena välineenä
AU630099B2 (en) Non-reverting rna viruses
NO891717D0 (no) Ekspresjon av hiv 24 kda gag-protein i metylotrofe gjaersorter.
DE68929084D1 (de) Arzneimittel zur Verhinderung einer Infektion mit dem für AIDS verantwortlichen Virus
AU2880495A (en) Use of pharmaceutical agents for alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 355905

Country of ref document: ES